![]() |
JOURNAL TOOLS |
Publishing options |
eTOC |
To subscribe |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Reprints |
Permissions |
Share |


YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
REVIEWS HEPATOLOGY IN 2009
Minerva Gastroenterologica e Dietologica 2009 March;55(1):23-35
Copyright © 2009 EDIZIONI MINERVA MEDICA
language: English
The management of hepatitis C
Pan J. J., Firpi R. J.
Section of Hepatobiliary Diseases and Liver Transplantation Division of Gastroenterology, Hepatology and Nutrition Department of Medicine, University of Florida, Gainesville, FL, USA
Hepatitis C is a serious public health problem with more than 170 million chronic carriers worldwide. Although hepatitis C infection can be cured in up to 40% of patients, current treatment is not ideal and is associated with a wide spectrum of side effects and complications. Therefore, emerging evidence suggests that patients can receive tailored therapy based on their viral kinetic changes during treatment. With better knowledge of hepatitis C viral genome and life cycle, compounds so called “Specifically Targeted Antiviral Therapy for HCV or STAT-C” are under development. This review will discuss current therapies and recent advances in new therapies for hepatitis C.